Abstract Clinical studies use a wide variety of health status measures to measure health related quality of life, many of which cannot be used in cost-effectiveness analysis using cost per quality adjusted life year (QALY). Mapping is one solution that is gaining popularity as it enables health state utility values to be predicted for use in cost per QALY analysis when no preference-based measure has been included in the study. This paper presents a systematic review of current practice in mapping between non-preference based measures and generic preferencebased measures, addressing feasibility and validity, circumstances under which it should be considered and lessons for future mapping studies. This review found 30 studies reporting 119 different models. Performance of the mappings functions in terms of goodness-of-fit and prediction was variable and unable to be generalised across instruments. Where generic measures are not regarded as appropriate for a condition, mapping does not solve this problem. Most testing in the literature occurs at the individual level yet the main purpose of these functions is to predict mean values for subgroups of patients, hence more testing is required.
Introduction
A common approach to assessing the outcomes of health care is to obtain patient reported descriptions of health status across various dimensions and then to apply a standardised numerical scoring system. There are many different measures of health, including several hundred condition-specific measures of health designed for use in specific medical conditions or groups of condition [1] , and a number of generic measures designed to cover the core dimensions of health that are relevant across all medical conditions. Health measures can also be distinguished in terms of whether they generate a profile of dimension scores or a single index and if they produce a single index, whether or not the index has been derived using simple summation of item scores or by using preference weights obtained from patients or the general public (known as preference-based measures or multi-attribute utility scales).
Patient-reported measures of health have become widely used as primary or secondary outcomes. There is little agreement on which precise instruments should be used for this purpose. For assessing clinical effectiveness, there is disagreement on whether to use a generic or conditionspecific measure, and between condition-specific measures there is often disagreement amongst clinical researchers on the most appropriate instrument. Profile measures provide scores for each domain and contain a large amount of information, but as these scores cannot be easily aggregated they are less suitable for comparisons across interventions or programmes. In contrast, preference-based measures produce a single score but typically contain fewer domains or items. As a result different measures are often used for the same patient groups, presenting a substantial barrier to evidence synthesis.
Many of the instruments used in clinical trials and other studies cannot be used in cost-effectiveness analysis to estimate cost per quality adjusted life year (QALY) as they are not preference-based. The QALY is a measure of health that combines both quality and quantity of life into a single number, where the 'quality' of life is measured using a health state utility value estimated using a preference-based measure of health. Health state utility values can also be useful for assessing clinical effectiveness as they deal with trade-offs made between outcomes.
Health state utility values are usually based on generic instruments (e.g. EQ-5D) that permit comparisons between patient groups, though condition specific preference-based measures are also used [2] . There has been some debate about the most appropriate preference-based generic measure to use in cost-effectiveness analyses. Whilst the EQ-5D is the most widely applied in recent years [3] , the HUI3 [4] , QWB [5] , SF-6D [6] and others continue to be used. However, different preference-based measures have been shown to generate different values on the same sample of patients [4, 7, 8] . Furthermore, many key clinical trials on the efficacy of new interventions do not have a generic measure, and FDA guidance on using patient reported outcome measures in support of promotional claims seems to further discourage the use of generic measures for cost-effectiveness analysis for pivotal trials designed for seeking licensing approval [9] . This lack of use of generic preference-based measures is a barrier to populating economic models with the best evidence on effectiveness.
Mapping is one solution that is gaining popularity as it enables health state utility values to be predicted when no preference-based measure has been included in the study. This approach involves estimating the relationship between a non-preference-based measure and a generic preferencebased measure using statistical association (also known as 'cross-walking' [10] or estimating exchange rates between instruments), and requires a degree of overlap between the descriptive systems of the two measures and that the two measures are administered on the same population. Typically, mapping uses two datasets: an estimation dataset that contains respondents' self-reported scores for their own health using two or more preference and non-preference based measures, and a study dataset containing only the non-preference based measure. Regression techniques are used on the estimation dataset to estimate a statistical relationship between the measures, and the results are then applied to the study dataset to obtain predicted health state utility values.
Mapping by statistical association is a better approach than trying to 'map' between measures by, for instance, using the judgement of 'experts'. The use of judgementbased methods has been criticised for its arbitrariness [11] and does not involve any attempt to estimate the uncertainty around the mapping. Therefore the validity of such mappings is questionable and the only way to test them is by empirically comparing the judgements against real data.
Different estimation models can be used in mapping studies (see Table 1 , adapted from [12] ). Model (1) is the simplest additive model, which regresses the target measure (such as the EQ-5D) onto the total score of the starting measure (e.g. SF-36, HAQ, HAD, etc.). This is also the most limiting specification since it assumes that the dimensions of the starting measure are equally important; all items carry equal weight; and response choices to each item lie on a similar interval scale (so, for example, the intervals between 'all of the time', 'most of the time', 'some of the time', 'a little of the time' and 'none of the time' are equal). These assumptions can be relaxed by modelling either dimension scores (model 2), item scores (model 3), or item responses (model 4) as independent variables. For these models, dimension and item scores will be treated as continuous variables and item responses are modelled as discrete dummy variables (e.g. 'all the time' is one, otherwise zero, and so forth). Using item responses can, however, result in a large number of independent variables (over 100 for SF-36) and so it may be useful to be selective in the items included in the model. In this case, items can be excluded for having coefficients that are non-significant or counter-intuitive in their sign prior to estimating a model with item responses (model 4). The assumptions of a simple additive model can be relaxed by including squared terms for dimension or item scores and interaction terms. Again these can generate a large number of variables and so researchers may also limit them to variables with significant main effects, at least for the item level models. A more complex approach to modelling the relationship would be to estimate separate models for each dimension of the target instrument (such as the 5 EQ-5D dimensions; i.e. models 5 and 6). For the EQ-5D, this creates a dependent variable that can be treated as continuous (model 5), but is more accurately treated as a discrete variable (model 6). These can be estimated by using any of the previous four specifications.
This paper presents a systematic review of current practice in mapping between non-preference-based measures and generic preference-based measures. The review includes mapping directly onto generic-based measures only and does not include conversions to utility metrics such as standard gamble, time trade-off and rating scales. It reviews the studies identified by a systematic search of the published literature and unpublished literature including discussion papers and conference abstracts. This review seeks to address the feasibility and overall validity of this approach, and the circumstances under which it should be considered, and to bring together any lessons for future mapping studies.
Literature review

Search
A systematic literature search was carried out. Based on a few core papers identified by the research group, a citation search was carried out using the Science Citation Index, Social Science Citation Index and Web of Science citation database. The citation search was undertaken both forwards and backwards. The forward search ensures that all papers that cite the core papers are reviewed. The backwards search ensures that all papers cited by the core papers are reviewed. A keyword search was also undertaken using the titles and abstracts in 15 electronic bibliographic databases covering biomedical and health-related sciences, social science, and the grey literature. Key words were combinations of: 'mapping/cross walking' and 'EQ-5D/SF-36/HUI/ QWB/NHP/SIP/health status/health profile'. The following databases were searched: Cinahl, Cochrane Central Database of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews (CDSR), DH-Data, Embase, Kings Fund, Medline, Medline Plus, NHS Database of Abstracts of Reviews of Effectiveness (DARE), NHS Economic Evaluations Database (NHS EED), NHS Health Technology Assessment (HTA) Database, OHE Health Economic Evaluations Database (HEED), Science Citation Index, Scopus, Social Sciences Citation Index, UK HESG (nonpeer reviewed discussion papers). Where possible, the searches were not restricted by publication type, language, or date of publication. These searches were supplemented by contacting known experts in the field.
Review
The overall aims of the review were to examine the feasibility and validity of the mapping approach, the circumstances under which it should be considered and to bring together any lessons for future mapping studies. These questions were addressed by extracting the data items listed in Table 2 on each model presented. These items cover a description of the instruments used, the population completing the instruments, model specification, methods of estimation, model fit, and predictive performance within and outside the estimation sample. In addition, any important comments from the author(s) were noted. Data extraction on all 31 papers was undertaken by two members of the research team and summarised in Excel using the headings shown in Table 2 , which had been agreed by all team members.
Findings
Studies included
A total of 1,319 papers were identified (1,277 by literature searches). The number of relevant papers was reduced to 227 based on a review of the titles, and subsequently to 38 based on a review of abstracts. Papers were not assessed on the basis of study design, participants, setting or quality, only on whether they involved mapping between a non-preference measure and a preference-based measure of health. Among these 38 papers, 3 were excluded as only conference abstracts could be found (after contacting the authors), and 1 paper was excluded as it did not include sufficient information for extraction. Another three papers were excluded because they were not based on empirical methods and one paper was excluded as it mapped between preference-based measures. This left a total of 30 papers for review that covered 119 different models. An appendix tabulating all the estimation models is available on request from the corresponding author.
Mapping between measures of health 217
Details of the 30 studies are presented in Table 3 . Mapping between measures is a new research area with most papers (27) published or produced after 2000, with the remaining three papers published 1996-1998. Out of the 30 papers, 19 are published in non-clinical journals including: Medical Decision Making (7 papers), Value in Health (3 papers), Medical Care (2 papers), Health Economics (1 paper), Quality of Life Research (1 paper) Journal of Health Economics (1 paper), Journal of Outcomes Research (1 paper), Medical Journal of Australia (1 paper) and European Journal of Health Economics (1 paper); and four papers are published in specific clinical journals. Out of the remaining eight papers, three are conference papers (with sufficient detail), one is a published discussion paper and four are unpublished project reports.
General description of studies
All studies involved the mapping of a non-preference based measure of health (the ''starting measure'') onto a preference-based measure of health (the ''target measure''). The most popular target measure used for mapping was the EQ-5D with 15 studies (14 used the United Kingdom MVH value set and one used the United States value set), followed by HUI/HUI2/HUI3 with 8 studies, SF-6D with 5 studies, AQoL with 2 studies, QWB with 1 study and 15D with 1 study. On the right hand side of the mapping equation, the most widely used starting measures were SF-12 (six studies) and SF-36 (seven studies). The remainder consisted of various condition specific instruments intended to capture patient-perceived quality of life covering asthma, rheumatoid arthritis, osteoarthritis, overactive-bladder, irritable bowl syndrome, intermittent claudication, dental, dyspepsia, obesity, hydrocephalus, breast disorder and heart disease, the RAND-36 and Nottingham health profile and self-assessed health (SAH) question (two studies). One study mapped clinical measures onto EQ-5D in angina patients.
The sample size (number of people giving responses) used in the mapping studies ranged from 68 to 23,647. Clinical trials were the most common source of data. Respondents were also recruited from populations in the community, hospital and primary care. Six studies used large panel survey data, such as the United States Medical Expenditure Panel Survey and the Health Survey for England.
Model specification
The most widely used model was the additive model. Most studies used total, dimension and item scores as the independent variables and some entered dummy variables representing the level of each item. Out of the 119 models reviewed, 35 models included interaction terms; 19 models incorporated transformations of the main effect such as square terms; 6 models included other health measures (years since onset of condition or disability status); 15 models included clinical measures; and 34 models considered respondents' personal characteristics, such as age, gender, race and income. Moving from total to dimension, to item level models or adding interaction and other terms had quite modest or negligible improvements. Increasing model complexity only rarely had a major impact on the range of scores being predicted and goodness-of-fit, for example the mapping between IBDQ to EQ-5D where R 2 increased from 0.45 to 0.69 after incorporating squared terms of dimension scores [13] . Twenty-six studies used the preference-based index score as the dependent variable, and the remaining four studies used the five dimensions of the EQ-5D as the dependent variable [12, [14] [15] [16] . 
Estimation
Most mapping functions have been estimated by OLS, though some researchers have explored generalised linear models with random effects, adjusted least square regression model (ALS), weighted least squares, Tobit model, censored least absolute deviation model (CLAD) and nonlinear models. Tobit and CLAD models are appropriate for censored or bounded data and may be used if the utility scores exhibit a ceiling effect, where a large proportion of subjects are in full health with a utility score of 1. Only two studies used CLAD [17, 18] and only one used Tobit [18] . One study used OLS, Tobit and CLAD [18] and found that CLAD performed best using mean prediction error and the Tobit model performed worst. For models with a discrete dependent variable (e.g. EQ-5D dimension level) then researchers have used ordinal logit and multinomial logit regression models. These latter models generate a probability distribution across dimension levels and there is a subsequent stage of imputing a single level for calculating a single index value for the respondent. One way for doing this has been to choose the highest probability level [12] . In a recent study, researchers used a Monte Carlo procedure to select from the distribution [16] .
Performance
Studies commonly report the model's explanatory power in terms of adjusted R 2 . Overall, models mapping a generic onto a generic preference-based measure (e.g. SF-12/36 to EQ-5D, NHP to SF-6D, and SF-36 to QWB) achieved an R 2 or adjusted R 2 of more than 0.5 within sample. There was little reduction in the goodness-of-fit from testing the mapping function on samples selected randomly from the same dataset as the estimation samples. The fit of functions mapping from condition specific to generic measures is more variable. One of the poorest fitting models was for the Overactive Bladder Questionnaire (OABq) onto the SF-6D, which achieved an adjusted R 2 of 0.17 [19] . One of the better models was between the International Weight Quality of Life Questionnaire (IWQoL) and the SF-6D, which managed 0.51 [20] . Figure 1 shows the distribution of R 2 statistics for generic to generic measures and condition-specific to generic measures. Explanatory power, however, has little value in comparing models estimated using different methods of estimation (see below for details). The authors have also assessed performance in terms of the sign, significance and consistency of the estimated coefficients. At least for main effects, coefficients should be negative (i.e. the more severe the health problem, the lower the preference index), and the more severe the item levels in model (4) the larger the negative coefficient. However, for some descriptive systems there is some ambiguity regarding the ordering of statements (e.g. between 'your health limits you a little in bathing and dressing' vs 'your health limits you a lot in moderate activities' in the SF-6D). Furthermore, interaction terms can interfere with these orderings and so are not reliable. For some models, item levels were merged to remove inconsistencies.
The purpose of mapping functions is to predict health state utility values in other datasets, so the model should be assessed using the accuracy of its predictions. Measures of explanatory power, for example R 2 and adjusted R 2 , are not a useful basis for assessing model performance of mapping functions as they focus upon how well the model explains the dataset it was estimated on. R 2 and adjusted R 2 also do not show whether the mapping function is appropriate for the entire dataset, for example the mapping function may have good explanatory power for mild health states but poor explanatory power for severe health states. A better method for assessing mapping functions is to examine the difference between predicted and observed values by calculating mean error (ME), mean absolute error (MAE) or root mean squared error (RMSE). These can provide an indication of the size of the prediction errors. Models can also be compared using the numbers or proportion of individual level absolute errors greater than some cut-off (e.g. 0.05 or 0.10) or within 5 or 10% of the observed value. The errors can be calculated at the individual level, health state level or aggregate level. Errors at the individual level tell us how well the model performs on the dataset it was estimated on but are less important in most practical applications that examine groups of patients. Errors can also be estimated at a health state level to indicate variability across individuals with the same level of health. The most relevant for economic evaluation are errors estimated at the aggregate level as these can be aggregated across groups of patients receiving different treatments. Mapping papers rarely specify how the errors have been calculated, which creates problems for comparison across papers.
Mean error for the 119 models ranged from 0.0007 to 0.042 and was nearly zero for the OLS models (as would be predicted). Mean error for OLS models will be near zero due to the estimation technique, meaning that MAE or RMSE are more useful measures for comparing across different models or estimation techniques. MAE at the individual level ranged from 0.0011 to 0.19 and RMSE ranged from 0.084 to 0.2. These typically represented a percentage error of up to 15% of the overall scale range of the dependent variable. For example, for a model with EQ-5D as the dependent variable the error would be typically under 0.24, which is 15% of the overall EQ-5D range (1.594).
The normality of prediction errors can be examined using the Jarque-Bera test, but this is not used in OLS models since these are unbiased by definition. What is potentially more important is the pattern of errors across the scale of the dependent variable. ME, MAE and RMSE can be reported for subsets of the index range, such as for EQ-5D B 0.5 and EQ-5D [ 0.5, to show whether the errors are affected by poor health. Only a few studies have examined this and some of those have found that the degree of error is not evenly distributed across the scale of the dependent variable. This problem was shown in two studies, one using a condition specific [12] and the other a generic instrument [16] as the start measure. Overall, the level of error is far greater at the lower (severer health) end. Gray et al. [16] , for example, found that the MAE varied from 0.065 to 0.109 for EQ-5D index values from 0.7 to 1.00, but for values less than 0.7 the MAE was over 0.30. Scatter plots have found that there was a tendency for EQ-5D models to overpredict values at the lower end and underpredict at the upper end of the EQ-5D. This was despite the inclusion of interaction and squared terms. These papers also found that the predicted values from the mapping functions tend to have lower levels of variance than the original observed values. Model performance is often assessed on the estimation dataset used to estimate the model, which is referred to in the literature as within-sample testing. Another strategy that was occasionally used was to estimate the model on a sub-sample of the full data (the 'estimation' sample) and then to test the model on the remaining sample (the 'validation' sample). Ten papers used out-of-sample tests and found little reduction, if any, in the performance of the models. However, these tests do not examine the performance of the model in truly independent samples.
Discussion
This review found 30 studies reporting a total of 119 different models. The studies undertook a range of different modelling methods, but the most common was a simple additive model estimated by OLS with the preferencebased index as the dependent variable, with the independent variables being dimension or item scores. More complex specifications were examined that included interaction and squared terms, non-health variables (e.g. socio-demographics) and different methods of estimation. These studies clearly show that the mapping approach is feasible, but the validity of the models in terms of goodness-of-fit and error of prediction at the individual level was highly variable. Explanatory power ranged from 0.17 to 0.71, and RMSE from 0.084 to 0.2. For those studies that examined the pattern of the error, they found the RMSE increased with the severity of the condition while mapping from SF-12 or SF-36 onto EQ-5D.
This paper has reviewed all literature meeting the search criteria regardless of study design, quality or purpose, whereas the question of whether mapping is a valid method for generating preference-based indices depends on the circumstances. In a situation where the analyst does not have any other data, some of the poorer models might still be acceptable. This may happen in economic evaluations alongside clinical trials where a non-preference-based condition-specific measure has been used, or where an analyst is seeking to synthesise data across studies and does not want to limit the evidence base to those studies using a particular preference-based measure. However, the potential degree of uncertainty and likely error must be fully explored. At the individual level, the RMSE was often quite high, and larger than published minimal important differences for these measures of between 0.041 and 0.071 [21] , which has implications for cost-effectiveness analysis using these predicted health state utility values. However, the purpose of mapping functions is to predict differences across groups of patients or differences between arms over time in clinical trials, and not between individual level index values. Work undertaken after this review was completed indicates that the size of the errors in predicting mean EQ-5D indices for patient groups from SF-36 data may be quite modest [22] . However, this was only for a limited range of patient groups. Other work also undertaken after this review was completed indicates that patients with more severe health problems may have gains under-estimated by the mapping function on the basis of existing evidence relating SF-36 to EQ-5D [23] . Most published studies have not examined whether such systematic patterns exist in the predictions of their models. This may have important implications for cost effectiveness analysis that uses mapping to generate health state utility values.
For prospective decisions about which instruments to use in future studies, the decision maker also needs an estimate of the error relevant to the population of interest (e.g. disease, severity and size of sample) to decide whether the error in these models is acceptable. The likely implications of any error in the estimation of differences or changes over time must be weighed against the additional cost of using a generic preference-based measure directly in the study or application being considered.
For mapping from condition-specific measures, the degree of error tended to be larger, although it varied across patient groups and/or conditions. However, the use of mapping to derive preference-based generic indices from condition-specific measures raises a more fundamental concern. Mapping assumes that there is a conceptual overlap between what is being measured by the two measures, and further that the preference-based target measure covers all important aspects of health of the nonpreference-based start measure. In other words, the strength of the mapping function depends on the degree of overlap between the two descriptive systems. Where there are important dimensions of one instrument not covered by the other, this may undermine the model. Where the generic measure does not cover certain dimensions of the nonpreference-based condition-specific measures that are regarded as important this could be an important weakness. EQ-5D does not, for example, contain a dimension for energy or vitality. So it is not surprising that, in published mapping functions from the SF-12 or SF-36 to EQ-5D, energy has a small and non-significant coefficient. Furthermore, condition-specific measures may not capture all side effects of treatments or co-morbidities. Another source of weakness can arise from differences in the severity range covered for a given health dimension. The SF-36 physical functioning dimension, for example, has been demonstrated to suffer from floor effects (i.e. large numbers of patients at, or near, the lowest score) and so it is not likely to be as good at predicting at the lower end. These problems can be more dramatic in condition-specific measures.
Where generic measures are not regarded as appropriate for the condition, due to either a lack of relevance or insensitivity, then mapping from the condition-specific measure onto a generic measure does not solve this problem. Indeed, the mapping function is likely to perform poorly, as was found in the case of the Over-Active Bladder Questionnaire [19] . An alternative approach in these circumstances is to estimate a preference-based index directly from the condition-specific measure, as has been done with the King's Health Questionnaire [24] or the Overactive Bladder Questionnaire [25] .
There are important lessons to be learnt about the methodology for undertaking mappings. The first is that the population used in the mapping process should cover the range of clinical and demographic characteristics of the sample on which the mapping function is ultimately going to be applied. In terms of model specification, most studies found that a simple additive model with an index score as the dependent variable and main effects of either total or dimension scores as independent variables, performed nearly as well as those for more complex models. Greater complexity came with little gain in most cases, but small gains come at little cost in terms of computing time.
The most common method of estimation was OLS. There is a concern in the literature that the standard OLS regression models under-estimate the level of uncertainty in the estimates [26] . This results from a centering around the mean caused by assuming that respondents who complete the start measure (e.g. SF-36) in one way would also complete the target instrument in the same way (EQ-5D). The result is a lower variance around the mean estimates. The importance of this problem depends on the way the data are going to be used. In large pooled analyses this may be of little importance. More of a problem is that the systematic pattern referred to earlier of over-predicting at the lower end may be partly a result of this. This problem still existed for the multinomial logit model used to predict the probability of response across the dimension levels of the EQ-5D. There may be other solutions to the problem, such as the application of a Bayesian approach (as has been used successfully in modelling health state values [27] ).
This review addressed a number of questions about the use of functions to map between non-preference based and generic preference-based measures. It found a surprisingly large body of literature. The performance of the mapping functions in terms of goodness-of-fit and prediction was variable and so it is not possible to generalise across instruments. Performance is related to the degree of overlap in content between the instruments being mapped. The current literature is limited in the way that these models have been tested, since most testing has focussed on their use at the individual level, and yet the main purpose of these functions is to predict mean values for subgroups of patients (such as arms of trials). Further work is required to test the accuracy of these functions in more relevant contexts and over a larger range of instruments. This review has not excluded any papers on the basis of quality or study limitations. Further work is also required to develop a framework for the critical appraisal of mapping studies. This would enable policy makers to critically assess utility scores generated using mapping studies for use in cost effectiveness analysis. The use of mapping functions is always a second-best solution to using a preference-based generic measure in the first place (or arguably using a preference-weighted condition-specific measure), but it is often necessary for pragmatic reasons and so this remains an important of area of research.
